Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

Exclusion Criteria

• •Females who were breastfeeding
• •Males and females of reproductive potential who are unwilling to use an "effective", protocol-specified method(s) of contraception during the study
• •Positive test at Screening for HBsAg, anti-HBc IgM Ab, or anti-HIV Ab.
• •History of any other clinically significant chronic liver disease
• •Treatment with herbal/natural remedies with antiviral activity within 30 days prior to baseline.
• •Significant history of immunologically mediated disease, cardiac or pulmonary disease, seizure disorder or anticonvulsant use
• •History of ascites, variceal hemorrhage, hepatic encephalopathy, or conditions consistent with decompensated liver disease
• •Use of medications associated with QT prolongation within 30 days prior to dosing
• •Screening electrocardiogram (ECG) QTc value greater than 450 ms and/or clinically significant ECG findings
• •Personal or family history of Torsade de pointes.
• •Positive results for drugs of abuse test at screening
• •Abnormal hematological and biochemical parameters, including alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 5 times the upper limit of the normal range (ULN)
• •History of major organ transplantation with an existing functional graft
• •History of uncontrolled thyroid disease or abnormal thyroid-stimulating hormone (TSH) levels at screening
• •Clinically significant drug allergy to nucleoside/nucleotide analogs
• •History or current evidence of psychiatric illness, immunologic disorder, pulmonary, cardiac disease, seizure disorder, cancer or history of malignancy that in the opinion of the investigator makes the patient unsuitable for the study
• •History of systemic antineoplastic or immunomodulatory treatment within 6 months prior to dosing, or the expectation of such treatment during the study